Fruzaqla Adds Sparkle To Takeda’s First Half
Pen Helps Mainstay Entyvio
Continued growth for mainstay Entyvio and cancer newcomer Fruzaqla drove growth at Takeda in the fiscal first half, with the Japanese major brightening its outlook for the full year.
